Divi's Laboratories (DIVISLAB) — Financial Results

Divi's Laboratories reported strong Q2 FY2026 performance with consolidated total income of ₹2,860 crores (17% YoY growth) and PAT of ₹689 crores. H1 FY2026 total income reached ₹5,389 crores (16% YoY growth) with PAT of ₹1,234 crores. Custom synthesis now represents 56% of product mix, while generics comprise 45%. The company has raised FY26 capex guidance above ₹2,000 crores, having spent ₹1,550 crores in H1 across three new projects. Gross margins remain stable at ~60% despite competitive pricing pressures in generics.

📄 View Original Announcement (PDF)

📊 Stock Analysis — DIVISLAB ✨ Ask AI About This

About Divi's Laboratories Limited (DIVISLAB)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹1,79,470.03 Cr P/E: 72.4 ROE: 16.6% ROCE: 22.1%

View full DIVISLAB stock details →

📡 Get AI alerts when DIVISLAB files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track DIVISLAB — Free

💡 Ask AI about this filing

"How does this financial results affect Divi's Laboratories Limited's outlook?" "What did Divi's Laboratories Limited announce on 12 November 2025?" "Is this positive or negative for DIVISLAB?"

Ask AI Free →

📊 More DIVISLAB filings

See all DIVISLAB filings →

🔥 Also filed on 12 November 2025

TCS Tata Consultancy Services Limited Corporate Action TATAPOWER Tata Power Company Limited Financial Results TATASTEEL Tata Steel Limited Financial Results TATASTEEL Tata Steel Limited Financial Results TATASTEEL Tata Steel Limited Financial Results WIPRO Wipro Limited Corporate Action

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when DIVISLAB files new disclosures

Track DIVISLAB filings, board meetings, and corporate actions. Free email alerts at 5 PM.